LETTER TO THE EDITOR FOR COMMENTS ON RECENT ARTICLES
HIV pre-exposure prophylaxis (PrEP) – are we seeing the end of the HIV pandemic?
1
Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Poland
Submission date: 2025-06-06
Acceptance date: 2025-06-08
Online publication date: 2025-07-11
Corresponding author
Bartosz Szetela
Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical
Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical
HIV & AIDS Review 2025;24(3):249-251
TOPICS
REFERENCES (35)
2.
Horban A, Podlasin R, Cholewińska G, Wiercińska-Drapało A, Knysz B. Zasady opieki nad osobami zakażonymi HIV. Zalecenia PTN AIDS 2014. Warszawa: Polskie Towarzystwo Naukowe AIDS; 2014.
3.
Szetela B, Cielniak I, Kubicka J, Rojewski T, Katafias A, Jakubowski P, et al. Pre-exposure prophylaxis (PrEP) in Poland 2017 to 2021: lessons from a country with no national PrEP programme. Journal of the International Aids Society 2022; 25. Supplement: HIV.
5.
Parczewski M, Leszczyszyn-Pynka M, Witak-Jędra M, Szetela B, Gąsiorowski J, Knysz B, et al. Expanding HIV-1 subtype B transmission networks among men who have sex with men in Poland. PLoS One 2017; 12: e0172473. DOI: https://doi.org/10.1371/journa....
6.
Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny. Zakażenia HIV i zachorowania na AIDS w Polsce. 2022. Available at: https://wwwold.pzh.gov.pl/oldp... (Accessed: 10.03.2024).
7.
Samra R, Fairley C, Ong J, Aung ET, Chow EP. Changes in HIV post-exposure prophylaxis prescriptions before and after the introduction of HIV pre-exposure prophylaxis at a sexual health clinic in Melbourne, Australia, 2011-2021. Aust N Z J Public Health 2024; 48: 100179. DOI: 10.1016/j.anzjph.2024.100179.
8.
Xia Q, Edelstein ZR, Katz B, Bertolino D, Berry A, Tsoi BW, Torian LV. Impact of HIV preexposure prophylaxis prescriptions on HIV diagnoses in New York City. AIDS 2024; 38: 1412-1423.
9.
Sullivan A, Saunders J, Desai M, Cartier A, Mitchell HD, Jaffer S, et al. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment. Lancet HIV 2023; 10: e790-e806. DOI: 10.1016/S2352-3018(23)00256-4.
10.
Szetela B. PrEP – what we have achieved in CEE and what needs to be done. EACS Standard of Care for HIV and Co-infections in Europe meeting, Brussels, 13-14 October 2022.
11.
European Centre for Disease Prevention and Control. HIV stigma in the healthcare setting. Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia. Stockholm: ECDC; 2024.
12.
Dashti AS, Joulaei R, Amiri S, Joulaei H. Knowledge, attitude, and practice of blood-borne diseases among healthcare providers in two selected educational hospitals in Southwest Iran. HIV AIDS Rev 2022; 21: 256-260.
13.
Bohdziewicz A, Goździalska M, Mikuła T, Wiercińska-Drapało A. What do Polish students know about HIV infections after 35 years of the first confirmed case? HIV AIDS Rev 2022; 21: 284-289.
14.
Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al.; ANRS PREVENIR Study Group. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV 2022; 9: e554-e562. DOI: 10.1016/S2352-3018(22)00133-3.
15.
Szetela B, Serwin K, Bozejko M, Zinczuk A, Zielinska K, Lapinski L, et al. HIV incident infections during pre-exposure prophylaxis (PrEP) use in Wroclaw, Poland, 2017–2023: a real-life experience. Sex Transm Infect 2025. DOI: 10.1136/sextrans-2024-056329.
16.
Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021; 385: 595-608.
17.
Delany-Moretlwe S, Hughes J, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022; 399: 1779-1789.
18.
Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med 2024; 391: 1179-1192.
19.
Kelley C, Acevedo-Quiñones M, Agwu A, Avihingsanon A, Ben-son P, Blumenthal J, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med 2025; 392: 1261-1276.
20.
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-422.
21.
Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372: 509-518.
22.
Baeten J, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
23.
Eshun SN, Tampah-Naah AM, Udor R, Addae D. Awareness and willingness to use pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) among sexually active adults in Ghana. HIV AIDS Rev 2023; 22: 329-336.
24.
Rodger A, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019; 393: 2428-2438.
25.
Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019; 321: 1380-1390.
26.
Biała M, Mączyńska B, Starzyński K, Rurańska-Smutnicka D, Secewicz A, Szuba P, Szetela B. Antimicrobial resistance of Neisseria gonorrhoeae isolates among men who have sex with men in Lower Silesia, Poland. Pathogens 2024; 13: 890. DOI: 10.3390/pathogens13100890.
27.
Szetela B, Łapiński Ł, Giniewicz K. Very high incidence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum among low-risk MSM in an Outpatient Clinic in Wroclaw, Poland in 2019-2020. Int J Environ Res Public Health 2023; 20: 2582. DOI: https://doi.org/10.3390/ijerph....
28.
Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure Doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023; 388: 1296-1306.
29.
Palacios R, Gómez-Ayerbe C, López-Jodar M, Martín-Cortés S, Pérez-Hernández I, Prolo A, et al. Post-exposure prophylaxis with doxycycline (DoxyPEP) in a cohort of men who have sex with men (MSM) in high risk for sexually transmitted infections (STI): the PRIDOX study. Abstract Supplement HIV Glasgow 10-13 November 2024, Glasgow, UK/Virtual. J Int AIDS Soc 2024; 27 Suppl 6: e26370. https://doi.org/10.1002/jia2.2....
30.
Bruxvoort K, Lewnard J, Chen L, Tseng HF, Chang J, Veltman J, et al. Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California. Clin Infect Dis 2023; 76: e1341-e1349. DOI: https://doi.org/10.1093/cid/ci....
31.
Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley R, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis 2022; 22: 1011-1020.
32.
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 3: 308-317.
33.
Estcourt C, Alana Y, Rakb N, Goldberg D, Cullen B, Steedman N, et al. Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. AIDS 2021; 35: 665-673.
34.
Traeger MW, Leyden WA, Volk JE, Silverberg MJ, Horberg MA, Davis TL, et al. Doxycycline postexposure prophylaxis and bacterial sexually transmitted infections among individuals using HIV preexposure prophylaxis. JAMA Intern Med 2025; 185: 273-281.
35.
Adelakun A, Dolph M, Matthews E, Oglesby A, Campbell K, Davis A, et al. Cost‐effectiveness and public‐health impact of cabotegravir long‐acting injectable for HIV pre‐exposure prophylaxis in Canada. Abstract Supplement HIV Glasgow 10-13 November 2024, Glasgow, UK/Virtual. J Int AIDS Soc 2024; 27 Suppl 6: e26370. DOI: https://doi.org/10.1002/jia2.2....
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
